Cancer Research Insights & Advancements

Explore updates on our innovative clinical trials, advancements in cancer research, fundraising efforts and the latest developments in oncology.

For media inquiries: media@marycrowley.org

Sort By

Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.

A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.

First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.

Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.

Intravenous infusion (IV) or intracavitary perfusion (IP) of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody: Analyses of two phase 1 studies.

Long-term efficacy, safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC)

Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12CMutated Metastatic Colorectal Cancer

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

Pages: 1234567891011121314151617181920212223

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000

For media inquiries: media@marycrowley.org

Cancer Research Insights & Advancements

Subscribe to Our Newsletter

Connect With Us